Boston Scientific (NYSE: BSX), a medical device company, reported second-quarter results that exceeded analyst expectations for revenue and adjusted earnings, and raised its full-year sales outlook. The company posted adjusted earnings per share of $0.86, surpassing the $0.83 consensus estimate, while revenue reached $5.442 billion, exceeding analyst expectations of $5.37 billion. Revenue increased 7.5% on a reported basis compared to the prior-year period. Boston Scientific also completed its previously announced $2 billion accelerated share repurchase program during the quarter.